Purchase Order 75F40119P10232
Award Date 6/14/19
Potential Completion Date 6/18/24
Potential Value $75K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide a diagnostic check and system upgrades for the MiSeq Whole Genome Sequencer at six FDA laboratories. The $84,733.20 contract has a completion date of December 31, 2022 and was sole-sourced to Illumina due to the proprietary nature of the MiSeq technology. Illumina has previously provided sequencing systems,...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the procurement of the MiSeq whole genome sequencing instrument, a genome sequencer, with a ceiling value of $166,207.78 and a period of performance through June 30, 2029. The contract is not set aside for any specific business designation. Illumina holds multiple federal...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents, for the delivery of 3 Illumina MiSeq sequencing systems. The $284,971.50 contract has an April 30, 2019 completion date and does not use any set-aside provisions. Illumina has a history of providing sequencing equipment and consumables to support genomic research and diagnostics at various federal...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing instruments and related products, for the provision of a MiSeq sequencing instrument and a one-year preventative maintenance agreement. The total potential value of this contract is $109,857.00. Illumina has a history of providing sequencing systems and services to support genomic research and diagnostics across various federal...
- This is a firm fixed-price delivery order awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a for-profit manufacturer of genetic sequencing instruments and reagents. The $87,870.00 contract is for the provision of a MiSeq DNA sequencing system and related consumables. The award has no set-aside designation. Illumina has previously been awarded prime contracts and subcontracts by various federal agencies, including the National Institutes of Health (NIH), Centers for Disease...
- This is a firm fixed price delivery order awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based analytical instruments and reagents for genetic and genomic analysis. The contract is for the provision of a MiSeq sequencing instrument to support the FDA's genomic sequencing and analysis work, with a ceiling value of $81,810. The contract is not associated with a set-aside or a larger contract vehicle, and there is no indication of any...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The $114,681.00 contract is for the delivery of a MiSeq System, a high-throughput next-generation DNA sequencing platform used to support life science research, applied markets, and molecular diagnostics. This award does not have a set-aside designation. Illumina has a history of providing...
- The Department of Health and Human Services Food and Drug Administration awarded a $136,975.00 firm fixed price purchase order to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents. The contract is for MiSeq sequencing service agreements covering four instruments, with a performance period ending on March 8, 2023. Illumina has previously received prime federal awards from agencies like the National Institutes of Health and Department of Veterans...
- The Food and Drug Administration (FDA) awarded a purchase order to Illumina, Inc. for an Illumina MiSeq i100Plus Sequencing System with a ceiling value of $97,054. The contract, which carries no set-aside designation, was awarded on September 18, 2025, with an ultimate completion date of October 20, 2025. The MiSeq i100Plus is an advanced DNA and RNA sequencing instrument that enables genomic analysis and research applications. Performance will take place at Illumina's San Diego, California...
- This $81,810 firm fixed price delivery order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for the provision of a MiSeq instrument and does not have a set-aside designation. Illumina has previously been awarded prime contracts and subcontracts by various federal agencies, including the National Institutes of Health (NIH), Centers for Disease Control and Prevention...